Global Relapsed/Refractory Follicular Lymphoma Market – Industry Trends and Forecast to 2029

Global Relapsed/Refractory Follicular Lymphoma Market, By Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Relapsed/Refractory Follicular Lymphoma Market Analysis and Size

The global relapsed/refractory follicular lymphoma market is expected to witness significant growth during the forecast period. Relapsed/refractory follicular lymphoma market has shown an exceptional penetration in developed economies in North America. Increasing prevalence of follicular lymphoma, high demand of targeted therapies and advanced healthcare facilities will likely enhance the market's growth. The endlessly improving healthcare infrastructure, along with the increase in disposable incomes of people in Asia Pacific region is expected to make the market grow in the forecast period. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global relapsed/refractory follicular lymphoma market in the forecast period 2022-2029. The expected CAGR of global relapsed/refractory follicular lymphoma market is tend to be around 4.7% in the mentioned forecast period. The market was valued at USD 1364 million in 2021, and it would grow upto USD 1969.64 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Relapsed/Refractory Follicular Lymphoma Market Scope and Segmentation

Market Definition

Follicular lymphoma is a kind of Non-Hodgkin lymphoma (NHL) in which cancerous group together in cluster arrangement in a lymph nodes and tissues around the lymph. In relapsed/refractory follicular lymphoma, the abnormal lymphocyte cells either reappear/come back after a period of successful treatment or when the response to treatment is ineffective. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Relapsed/Refractory Follicular Lymphoma Market Dynamics

Drivers

• Increase in Relapsed/Refractory Follicular Lymphoma

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL). As per the records of the Lymphoma Research Foundation, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed each year in the U.S. This boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to drive the market growth. The segment is expected to accelerate the global relapsed/refractory follicular lymphoma market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Drug Approvals

Market players are concentrating on approvals for relapsed or refractory diffuse large B-cell lymphoma therapeutics from regulatory authorities which is projected to boost the market growth. For instance, on February 8, 2021, Bristol Myers Squibb, received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), chimeric antigen receptor (CAR) T-cell therapy, used for diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B, in patients who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

• Higher Indulgence of Immunotherapy

The immunotherapy segment is projected to gain further attraction during the forecast period. Immunotherapeutics tend to have less adverse effects when compared to chemotherapeutics. Non-specificity, toxic side effects, and development of resistance associated with chemotherapy are most likely to suppress the growth of chemotherapeutics and boost the adoption of immunotherapeutics and other targeted treatments. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global relapsed/refractory follicular lymphoma market over a forecast period.

• High Cost

The huge expenditure of the treatment methods such as immunotherapy, chemotherapy, medications are surely hamper the market growth.

This global relapsed/refractory follicular lymphoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global relapsed/refractory follicular lymphoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Relapsed/Refractory Follicular Lymphoma Market

Rapidly growing cases of COVID-19 caused major disruptions to clinical trial execution in the U.S., impacting major stakeholders across the industry. Sponsors, CROs, and other organizations which supports drug development moved to remote working environments. Approximately 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.

According to National Center for Biotechnology Information (NCBI), April 29, 2020, many clinical trials suspended the trial enrollment to diminish the risk of contracting COVID-19, which has led to the postponement in the activation of new clinical trials. Furthermore, many companies have already missed the patients' follow-up in trials. Thus, the market was majorly impacted by COVID-19.

Global Relapsed/Refractory Follicular Lymphoma Market Scope

The global relapsed/refractory follicular lymphoma market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Chemotherapy
• Targeted Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Relapsed/Refractory Follicular Lymphoma Market Regional Analysis/Insights

The global relapsed/refractory follicular lymphoma market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global relapsed/refractory follicular lymphoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the increased prevalence of follicular lymphoma, high demand of targeted therapies and advanced healthcare facilities.

Asia-Pacific dominates the market due to the increase awareness about the diseases and rapidly disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Relapsed/Refractory Follicular Lymphoma Market Share Analysis

The global relapsed/refractory follicular lymphoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global relapsed/refractory follicular lymphoma market.

Key players operating in the global relapsed/refractory follicular lymphoma market include:

• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Aspen Pharma (South Africa)
• Spectrum Pharmaceuticals, Inc. (U.S.)
• Verastem, Inc (U.S.)